References
- Lublin F D, Reingold S C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907e11
- Jain K K. Evaluation of mitoxantrone for the treatment of multiple sclerosis. Expert Opin Invest Drugs 2000; 9: 1139–1149
- Mistry A R, Felix C A, Whitmarsh R J, et al. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med 2005; 352: 1529–1538
- Ramkumar B, Chadha M K, Barcos M, Saitd S NJ, Heyman M R, Baer M R. Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis. Cancer Genet Cytogenet 2008; 182: 126–129
- Hasan S K, Mays A N, Ottone T, et al. Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood 2008; 112: 3383–3390
- Sanz M A, Grimwade D, Tallman M S, et al. Guidelines on the management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113: 1875–1891
- Sanz M A, Fenaux P, Lo Coco F, European APL Group of Experts. Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence. Haematologica 2005; 90: 1231–1235
- Avvisati G, Lo Coco F, Diverio D, et al. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood 1996; 88: 1390–1398
- Voltz R, Starck M, Zingler V, Strupp M, Kolb H J. Mitoxantrone therapy in multiple sclerosis and acute leukemia: a case report of 644 treated patients. Mult Scler 2004; 10: 472e4